Loading
Life sciences · Journal article
Eurasia Journal of Science and Technology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To compare overall survival and safety of patients with metastatic gastric and gastroesophageal junction cancers treated with sintilimab with chemotherapy vs. chemotherapy only. In this study, we enrolled 60 with metastatic gastric cancer patients. Among them, 33 received treatment with chemotherapy combined with sintilimab, while the other 27 received chemotherapy alone. Demographic, clinical, and pathological data were analyzed. Of the 60 patients, 27 were treated with sintilimab plus chemotherapy and 33 with chemotherapy only. The addition of sintilimab increased the tumor response rate to chemotherapy (disease control rate [DCR]: 96.29% vs. 72.72%, P = 0.017). Furthermore, the combination therapy improved the progression-free survival (median: 8.41 months [95% CI: 5.59-11.22] vs. 6.03 months [95% CI: 3.90-8.16]) and overall survival (31.46 months [95% CI: 24.69-38.22] vs. 23.38 months [95% CI: 17.34-29.43]). Overall, the combined treatment group demonstrated good treatment tolerance. In patients with metastatic gastric and gastroesophageal junction cancers receiving first-line chemotherapy, the addition of sintilimab improved treatment outcomes compared with chemotherapy alone.